BeOne Medicines Ltd ADR(ONC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 65.61 | EPS (ttm) | 5.69 | Insider Own | 0.53% | Shs Outstand | 104.2M | Perf Week | -3.39% |
| Market Cap | 38.93B | Forward P/E | 36.33 | EPS next Y | 41.03% | Insider Trans | -65.55% | Shs Float | 103.7M | Perf Month | 2.21% |
| Enterprise Value | 35.72B | PEG | 0.49 | EPS next Q | 1.9 | Inst Own | 33.34% | Short Float | 1.73% | Perf Quarter | 15.92% |
| Income | 0.66B | P/S | 6.34 | EPS this Y | 177.06% | Inst Trans | 1.86% | Short Ratio | 4.67 | Perf Half Y | 28.39% |
| Sales | 6.14B | P/B | 8.16 | EPS next 5Y | 73.57% | ROA | 8.49% | Short Interest | 1.79M | Perf YTD | 22.89% |
| Book/sh | 45.78 | P/C | 7.4 | EPS past 3/5Y | - | ROE | 14.7% | 52W High | -3.94% ($388.66) | Perf Year | 17.83% |
| Cash/sh | 50.44 | P/FCF | 29.2 | Sales past 3/5Y | 55.88% 76.88% | ROIC | 9.5% | 52W Low | 47.02% ($253.95) | Perf 3Y | 119.04% |
| Dividend Est. | - | EV/EBITDA | 33.05 | EPS Y/Y TTM | 449.53% | Gross Margin | 86.76% | Volatility(W/M) | 2.98% 2.83% | Perf 5Y | 2.41% |
| Dividend TTM | - | EV/Sales | 5.81 | Sales Y/Y TTM | 34.39% | Oper. Margin | 15.06% | ATR (14) | 10.99 | Perf 10Y | 1015.51% |
| Dividend Ex-Date | - | Quick Ratio | 3.06 | EPS Q/Q | 143.77% | Profit Margin | 10.7% | RSI (14) | 54.96 | Recom | 1.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.4 | Sales Q/Q | 29.39% | SMA20 | 2.08% ($365.75) | Beta | 0.64 | Target Price | $437.83 |
| Payout | - | Debt/Eq | 0.4 | Earnings | 2026/11/5 | SMA50 | 2.79% ($363.23) | Rel Volume | 0.72 | Prev Close | $366.05 |
| Employees | 12000 | LT Debt/Eq | 0.34 | EPS/Sales Surpr. | 23.45% 4.95% | SMA200 | 14.99% ($324.69) | Avg Volume(3M) | 0.38M | Price | $373.36 |
| IPO | 2016/2/3 | Option/Short | Yes/Yes | Trades | 8681 | Volume | 276,516 | Change | 2% |
💊 This is a global biotech company focused on anti-cancer therapeutics. Founded in 2010 and headquartered in Basel, Switzerland, the company, which changed its name from BeiGene and trades under the ticker ONC, is a large-cap biotech holding a pipeline of BTK inhibitors and other candidates for hematologic cancers and solid tumors, making it a key name riding the wave of expansion in the global oncology drug market.
Over the past 1 year, on the higher side
4% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
Next earnings report: November 5
7 days to go.
ONC earns at a steady pace
Of every $100 in sales, $15.06 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +177.1% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $6,561. Peers typically go for $3,451. It is about in line with its own 1-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 5 years ago, your return today would be +2.4%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 33.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #6 of 594 in the industry
Based on market cap of $39B.
RVMD#5 Revolution Medicines Inc $40B PER - 
ONC#6 BeOne Medicines Ltd ADR $39B PER 65.6 
RPRX#7 Royalty Pharma plc $37B PER 34.5 
GMAB#8 Genmab ADR $34B PER 45.4 
ALNY#9 Alnylam Pharmaceuticals Inc $31B PER 39.2 
FAQ
What kind of company is ONC?
ONC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ONC?
The market cap of ONC is approximately $38.9B, ranking 388 within its sector.
What is the P/E ratio of ONC?
ONC has a P/E ratio of approximately 65.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ONC?
ONC has recorded a 52-week high of $388.66 and a low of $253.95.
